Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patients with Episodic Migraine for the Determination of Molecular and Clinical Biomarkers (MAMBO II Study).

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519770-38-00

Acronym

MAMBO-II

Enrollment

Registered

2025-04-01

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

Temporal evolution of GRP, AMY , VIP and PACAP-38 levels in blood and saliva (4 time points: Basal, begging migraine; peak-migraine; 2 hours post migraine treatment)

Interventions

DRUGSUMATRIPTAN

DRUGGLYCERYL TRINITRATE

DRUGRIMEGEPANT

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Temporal evolution of GRP, AMY , VIP and PACAP-38 levels in blood and saliva (4 time points: Basal, begging migraine; peak-migraine; 2 hours post migraine treatment)	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026